🚀 VC round data is live in beta, check it out!
Cantargia Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cantargia and similar public comparables like Coya Therapeutics, Cassava Sciences, Darya-Varia Laboratoria, Adocia and more.
Cantargia Overview
About Cantargia
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, as well as its antibody platform CANxx.
Founded
2009
HQ
Employees
22
Website
Sectors
Financials (LTM)
EV
$100M
Cantargia Financials
Cantargia reported last 12-month revenue of $26M and EBITDA of $7M.
In the same LTM period, Cantargia generated $25M in gross profit, $7M in EBITDA, and $6M in net income.
Revenue (LTM)
Cantargia P&L
In the most recent fiscal year, Cantargia reported revenue of $36M and EBITDA of $18M.
Cantargia expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $26M | XXX | $36M | XXX | XXX | XXX |
| Gross Profit | $25M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | — | XXX | XXX | XXX |
| EBITDA | $7M | XXX | $18M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 49% | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 47% | XXX | XXX | XXX |
| Net Profit | $6M | XXX | $16M | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 45% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cantargia Stock Performance
Cantargia has current market cap of $107M, and enterprise value of $100M.
Market Cap Evolution
Cantargia's stock price is $0.43.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $100M | $107M | -11.1% | XXX | XXX | XXX | $0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCantargia Valuation Multiples
Cantargia trades at 3.8x EV/Revenue multiple, and 14.0x EV/EBITDA.
EV / Revenue (LTM)
Cantargia Financial Valuation Multiples
As of April 10, 2026, Cantargia has market cap of $107M and EV of $100M.
Equity research analysts estimate Cantargia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cantargia has a P/E ratio of 16.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $107M | XXX | $107M | XXX | XXX | XXX |
| EV (current) | $100M | XXX | $100M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 14.0x | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBIT | 14.3x | XXX | 5.9x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | — | XXX | XXX | XXX |
| P/E | 16.9x | XXX | 6.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 6.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cantargia Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cantargia Margins & Growth Rates
Cantargia's revenue in the last 12 month declined by (91%).
Cantargia's revenue per employee in the last FY averaged $1.6M, while opex per employee averaged $0.8M for the same period.
Cantargia's rule of 40 is (6290%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cantargia's rule of X is (6439%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Cantargia Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (91%) | XXX | (99%) | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 49% | XXX | XXX | XXX |
| EBITDA Growth | (344%) | XXX | (211%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (6290%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (6439%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 59% | XXX | 41% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cantargia Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Coya Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cassava Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Darya-Varia Laboratoria | XXX | XXX | XXX | XXX | XXX | XXX |
| Adocia | XXX | XXX | XXX | XXX | XXX | XXX |
| Nykode Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cantargia M&A Activity
Cantargia acquired XXX companies to date.
Last acquisition by Cantargia was on XXXXXXXX, XXXXX. Cantargia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cantargia
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCantargia Investment Activity
Cantargia invested in XXX companies to date.
Cantargia made its latest investment on XXXXXXXX, XXXXX. Cantargia invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cantargia
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cantargia
| When was Cantargia founded? | Cantargia was founded in 2009. |
| Where is Cantargia headquartered? | Cantargia is headquartered in Sweden. |
| How many employees does Cantargia have? | As of today, Cantargia has over 22 employees. |
| Who is the CEO of Cantargia? | Cantargia's CEO is Damian Marron. |
| Is Cantargia publicly listed? | Yes, Cantargia is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Cantargia? | Cantargia trades under CANTA ticker. |
| When did Cantargia go public? | Cantargia went public in 2015. |
| Who are competitors of Cantargia? | Cantargia main competitors are Coya Therapeutics, Cassava Sciences, Darya-Varia Laboratoria, Adocia. |
| What is the current market cap of Cantargia? | Cantargia's current market cap is $107M. |
| What is the current revenue of Cantargia? | Cantargia's last 12 months revenue is $26M. |
| What is the current revenue growth of Cantargia? | Cantargia revenue growth (NTM/LTM) is (91%). |
| What is the current EV/Revenue multiple of Cantargia? | Current revenue multiple of Cantargia is 3.8x. |
| Is Cantargia profitable? | Yes, Cantargia is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cantargia? | Cantargia's last 12 months EBITDA is $7M. |
| What is Cantargia's EBITDA margin? | Cantargia's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Cantargia? | Current EBITDA multiple of Cantargia is 14.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.